Harvard Pilgrim Health Care Home
  HPHConnect
 
  Learn more.
  Sign up for HPHConnect.
Medical Management
E-Transactions
HPHConnect
Pharmacy
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Newsroom
Office Support
Products
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
 
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

September 2015

Prior Authorization Now Required for Orkambi


Effective immediately, Harvard Pilgrim is now covering the medication Orkambi with prior authorization. In July 2015, the FDA approved Orkambi (ivacaftor/lumacaftor), an oral agent that targets a specific subgroup of patients with cystic fibrosis.

Orkambi is indicated for treating patients 12 years and older, who have two copies of the F508del gene mutation. Having two copies of this mutation, one inherited from each parent, occurs in approximately half of the cystic fibrosis population in the U.S. In patients for whom the genotype is unknown, an FDA-approved test should be used to detect the presence of the patient-specific mutation.

Orkambi will be covered on the Premium formularies only, at the highest tier (Tier 3 on the 3-Tier and Tier 4 on the 4-Tier). Harvard Pilgrim’s Orkambi Clinical Review Criteria detail the requirements that must be met in order to obtain prior authorization. To request prior authorization, please complete the Orkambi Medication Request Form and fax it to MedImpact Healthcare Systems at 888-807-6643.

For more information, please visit the Pharmacy section of Harvard Pilgrim’s provider website or call Clinical Pharmacy Services at 617-509-1786.

Email this article to a colleague   


Network Matters Archives

Download printer-friendly version

HPHCURRENT EVENTS

Expanding our Medicare Advantage Service Area for 2016

ICD-10 Transition Approaching

Referral Procedure Change for Massachusetts Providers

ChoiceNet and Hospital Prefer 2016 Tiers

How Are We Doing? Tell Us!

CLINICIAN CORNER

Update on Hysterectomy Prior Authorization Policy

Prior Authorization Now Required for Orkambi

Synagis for Upcoming RSV Season

Depression Screening and Treatment

OFFICE ASSISTANT

HPHConnect: Inactive Account Management

PUBLICATION INFORMATION

Eric H. Schultz,
President and Chief Executive Officer

Robert Farias,
Vice President, Network Services

Annmarie Dadoly,
Editor

Joseph O'Riordan,
Writer

Kristin Edmonston,
Production Coordinator